Cabergoline (CED0004293)

Record Information

Version

1.0

Creation Date

2009-07-21 20:26:24 UTC

Update Date

2026-05-14 16:24:55 UTC

SynCED ID

CED0004293

Secondary Accession Numbers

CHEM002153
T3D2727

Identification

Common Name

Cabergoline

Class

Small Molecule

Description

Cabergoline is an exogenous solid with the formula C26H37N5O2 and an average molecular weight of 451.60 g/mol. Cabergoline belongs to the lysergic acids and derivatives, a subclass of ergoline and derivatives within the organic compounds. It is used as a dopamine agonist, an antiparkinson drug, and an antineoplastic agent. Recorded exposure occurs via the oral route, and the compound is found in healthcare, pharmaceuticals and veterinary products, including dopaminergic agents and gynecologicals. It is also recorded in household cleaning and consumer products, such as cigar cigarettes, non electric simulated smoking devices, and other smoking requisites, as well as in electrical and electronic equipment, including television systems and electrically stimulated smoking devices. The compound interacts with 20 recorded protein targets. It is a long-acting dopamine receptor agonist with a high affinity for D(2) dopamine receptors (DRD2), an interaction that produces an anti-Parkinsonian effect. Other protein targets include the D(3) dopamine receptor (DRD3), 5-hydroxytryptamine receptor 2A (HTR2A), Alpha-2B adrenergic receptor (ADRA2B), 5-hydroxytryptamine receptor 1D (HTR1D), and 13 other proteins. Additionally, cabergoline acts as an agonist for 5-hydroxytryptamine receptor 1B (HTR1B) and 5-hydroxytryptamine receptor 2B (HTR2B); this agonism is believed to be responsible for cardiac valvular disease and fibrotic reactions associated with the use of the compound.

Contaminant Type

Amide
Amine
Antineoplastic Agent
Antiparkinson Agent
Dopamine Agonist
Drug
Human Neurotoxin
Metabolite
Organic Compound
Synthetic Compound

Chemical Structure

MOL SDF PDB SMILES InChI

Synonyms

Value	Source
(8beta)-N-[3-(Dimethylamino)propyl]-N-[(ethylamino)carbonyl]-6-(2-propenyl)-ergoline-8-carboxamide	ChEBI
(8R)-6-Allyl-N-[3-(dimethylamino)propyl]-N-(ethylcarbamoyl)ergoline-8-carboxamide	ChEBI
1-((6-Allylergolin-8beta-yl)carbonyl)-1-(3-(dimethylamino)propyl)-3-ethylurea	ChEBI
1-[(6-Allylergoline-8beta-yl)carbonyl]-1-[3-(dimethylamino)propyl]-3-ethylurea	ChEBI
1-Ethyl-3-(3'-dimethylamionpropyl)-2-(6'-allylergoline-8'beta-carbonyl)urea	ChEBI
Cabergolina	ChEBI
Cabergolinum	ChEBI
Cabaser	Kegg
Dostinex	Kegg
(8b)-N-[3-(Dimethylamino)propyl]-N-[(ethylamino)carbonyl]-6-(2-propenyl)-ergoline-8-carboxamide	Generator
(8Β)-N-[3-(dimethylamino)propyl]-N-[(ethylamino)carbonyl]-6-(2-propenyl)-ergoline-8-carboxamide	Generator
1-((6-Allylergolin-8b-yl)carbonyl)-1-(3-(dimethylamino)propyl)-3-ethylurea	Generator
1-((6-Allylergolin-8β-yl)carbonyl)-1-(3-(dimethylamino)propyl)-3-ethylurea	Generator
1-[(6-Allylergoline-8b-yl)carbonyl]-1-[3-(dimethylamino)propyl]-3-ethylurea	Generator
1-[(6-Allylergoline-8β-yl)carbonyl]-1-[3-(dimethylamino)propyl]-3-ethylurea	Generator
1-Ethyl-3-(3'-dimethylamionpropyl)-2-(6'-allylergoline-8'b-carbonyl)urea	Generator
1-Ethyl-3-(3'-dimethylamionpropyl)-2-(6'-allylergoline-8'β-carbonyl)urea	Generator
1-Ethyl-2-(3'-dimethylaminopropyl)-3-(6'-allylergoline-8'-beta-carbonyl)urea diphosphate	HMDB
Cabaseril	HMDB
Galastop	HMDB
Cabergoline diphosphate	HMDB

Chemical Formula

C₂₆H₃₇N₅O₂

Average Molecular Mass

451.604 g/mol

Monoisotopic Mass

451.295 g/mol

CAS Registry Number

81409-90-7

IUPAC Name

1-[3-(dimethylamino)propyl]-3-ethyl-1-[(2R,4R,7R)-6-(prop-2-en-1-yl)-6,11-diazatetracyclo[7.6.1.0²,⁷.0¹²,¹⁶]hexadeca-1(16),9,12,14-tetraene-4-carbonyl]urea

Traditional Name

cabergoline

SMILES

[H][C@@]12CC3=CNC4=CC=CC(=C34)[C@@]1([H])C[C@H](CN2CC=C)C(=O)N(CCCN(C)C)C(=O)NCC

InChI Identifier

InChI=1S/C26H37N5O2/c1-5-11-30-17-19(25(32)31(26(33)27-6-2)13-8-12-29(3)4)14-21-20-9-7-10-22-24(20)18(16-28-22)15-23(21)30/h5,7,9-10,16,19,21,23,28H,1,6,8,11-15,17H2,2-4H3,(H,27,33)/t19-,21-,23-/m1/s1

InChI Key

KORNTPPJEAJQIU-KJXAQDMKSA-N

Chemical Taxonomy

Description

Belongs to the class of organic compounds known as lysergic acids and derivatives. These are alkaloids with a structure based on the lysergic acid skeleton.

Kingdom

Organic compounds

Super Class

Alkaloids and derivatives

Class

Ergoline and derivatives

Sub Class

Lysergic acids and derivatives

Direct Parent

Lysergic acids and derivatives

Alternative Parents

Substituents

Lysergic acid or derivatives
Indoloquinoline
Benzoquinoline
Quinoline-3-carboxamide
Pyrroloquinoline
Quinoline
3-alkylindole
Indole
Indole or derivatives
Isoindole or derivatives
3-piperidinecarboxamide
Piperidinecarboxamide
N-acyl urea
Aralkylamine
Ureide
Benzenoid
Piperidine
Dicarboximide
Heteroaromatic compound
Pyrrole
Urea
Tertiary amine
Tertiary aliphatic amine
Carbonic acid derivative
Amino acid or derivatives
Organoheterocyclic compound
Azacycle
Carboxylic acid derivative
Organooxygen compound
Organic oxide
Organopnictogen compound
Organic oxygen compound
Amine
Hydrocarbon derivative
Carbonyl group
Organic nitrogen compound
Organonitrogen compound
Aromatic heteropolycyclic compound

Molecular Framework

Aromatic heteropolycyclic compounds

External Descriptors

N-acylurea (CHEBI:3286 )

Biological Properties

Status

Detected and Not Quantified

Origin

Exogenous

Cellular Locations

Cytoplasm
Extracellular
Membrane

Biofluid Locations

Not Available

Tissue Locations

Not Available

Applications

Biological Roles

dopamine agonist (PMC11669403 )?

Chemical Roles

Not Available

Organoleptic Effects

Not Available

Physical Properties

State

Solid

Appearance

White powder.

Experimental Properties

Property	Value
Melting Point	102-104°C
Boiling Point	Not Available
Solubility	Insoluble

Predicted Properties

Property	Value	Source
Water Solubility	0.064 g/L	ALOGPS
logP	2.97	ALOGPS
logP	2.58	ChemAxon
logS	-3.8	ALOGPS
pKa (Strongest Acidic)	15.25	ChemAxon
pKa (Strongest Basic)	9.32	ChemAxon
Physiological Charge	2	ChemAxon
Hydrogen Acceptor Count	4	ChemAxon
Hydrogen Donor Count	2	ChemAxon
Polar Surface Area	71.68 Å²	ChemAxon
Rotatable Bond Count	8	ChemAxon
Refractivity	133.5 m³·mol⁻¹	ChemAxon
Polarizability	52.5 Å³	ChemAxon
Number of Rings	4	ChemAxon
Bioavailability	Yes	ChemAxon
Rule of Five	Yes	ChemAxon
Ghose Filter	No	ChemAxon
Veber's Rule	No	ChemAxon
MDDR-like Rule	Yes	ChemAxon

Spectra

Spectrum Type	Description	Splash Key	Deposition Date	View
Predicted GC-MS	Predicted GC-MS Spectrum	splash10-0a4u-9332300000-c399dad54a5ca1142e58	Not Available	View Spectrum
Predicted GC-MS	Predicted GC-MS Spectrum	Not Available	Not Available	View Spectrum
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum	splash10-0uk9-6612900000-09532480a6bc0ee23c8b	Not Available	View Spectrum
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum	splash10-0006-9547200000-4408faaf3f5607911d33	Not Available	View Spectrum
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum	splash10-0006-9230000000-e8bfe5d55836ee96fff9	Not Available	View Spectrum
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum	splash10-0udi-4004900000-a2459baf72baf4f7d4c0	Not Available	View Spectrum
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum	splash10-0fml-8138900000-802be7d5b4ed6f5ea2ea	Not Available	View Spectrum
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum	splash10-0006-9456000000-a805853927d5cdb1b2fa	Not Available	View Spectrum
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum	splash10-0udi-0000900000-789dda3470f1d5d2b188	Not Available	View Spectrum
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum	splash10-0zgi-3008900000-cefe7417b2ff493d14e7	Not Available	View Spectrum
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum	splash10-0zfr-4549000000-ffec92d47b323b6e170c	Not Available	View Spectrum
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum	splash10-0udi-0003900000-4c85bc032d2cb605ace4	Not Available	View Spectrum
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum	splash10-004i-1209000000-00a4b086d755fec1cdd3	Not Available	View Spectrum
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum	splash10-052o-3069000000-6aeb0c0daa38a57cc470	Not Available	View Spectrum

Toxicity Profile

Toxicity Values

Toxicity Value	Organism	Dose Descriptor	Route of Exposure	Predicted or Experimental	Toxicity Rating	Reference
219.0 Log mg/kg [120:390]	Rat	LD50	oral	predicted	Not Available	Not Available

Toxicity / Toxin Class

Not Available

Mechanism of Toxicity

Ergoline alkaloids have been shown to have the significant affinity towards the 5-HT1 and 5-HT2 serotonin receptors, D1 and D2 dopamine receptors, and alpha-adrenergic receptors. This can result in a number of different effects, including vasoconstriction, convulsions, and hallucinations. (2, 3, 4, 12) The dopamine D₂ receptor is a 7-transmembrane G-protein coupled receptor associated with G_i proteins. In lactotrophs, stimulation of dopamine D₂ causes inhibition of adenylyl cyclase, which decreases intracellular cAMP concentrations and blocks IP3-dependent release of Ca²⁺ from intracellular stores. Decreases in intracellular calcium levels may also be brought about via inhibition of calcium influx through voltage-gated calcium channels, rather than via inhibition of adenylyl cyclase. Additionally, receptor activation blocks phosphorylation of p42/p44 MAPK and decreases MAPK/ERK kinase phosphorylation. Inhibition of MAPK appears to be mediated by c-Raf and B-Raf-dependent inhibition of MAPK/ERK kinase. Dopamine-stimulated growth hormone release from the pituitary gland is mediated by a decrease in intracellular calcium influx through voltage-gated calcium channels rather than via adenylyl cyclase inhibition. Stimulation of dopamine D₂ receptors in the nigrostriatal pathway leads to improvements in coordinated muscle activity in those with movement disorders. Cabergoline is a long-acting dopamine receptor agonist with a high affinity for D2 receptors. Receptor-binding studies indicate that cabergoline has low affinity for dopamine D1, α₁,- and α₂- adrenergic, and 5-HT₁- and 5-HT₂-serotonin receptors.

Carcinogenicity (IARC Classification)

No indication of carcinogenicity to humans (not listed by IARC).

Minimum Risk Level

Not Available

Symptoms

Side effects of cabergoline include nausea, constipation, dry mouth, sleep disturbances, vertigo, depression, hypotension, and peripheral edema. Convulsive ergotism can cause painful seizures and spasms, diarrhea, paresthesias, itching, headaches, nausea and vomiting. Usually the gastrointestinal effects precede the central nervous system effects. As well as seizures there can be hallucinations and mental effects including mania or psychosis. Gangrenous ergotism causes dry gangrene as a result of vasoconstriction induced in the more poorly vascularized distal structures, such as the fingers and toes. Symptoms include desquamation, weak periphery pulse, loss of peripheral sensation, edema and ultimately the death and loss of affected tissues. (10, 13) Overdosage might be expected to produce nasal congestion, syncope, or hallucinations.

Treatment

Treatment for ergotism consists of vasodilators, anticoagulants and low molecular weight dextrans. If necessary, a sympathetic nerve blockade may be carried out, such as brachial plexus blockade. Temporary sedation (e.g. haloperidol) will be necessary in hallucination and diazepam is used for convulsions. There is no specific antidote. (11)

Health Effects

Health Effect	Relationship	Direction	Description	Reference

Exposure Sources

Source ID	Source	Sector	Reference
CEDs000010	Insecticides?Insecticides are synthetic chemicals designed to control or eliminate insect pests that threaten crops and other agricultural products.	Agriculture & land management	PubChem
CEDs000316	Gynecologicals?Gynecologicals encompass a range of synthetic chemicals used in the treatment of various women's health issues, including hormonal therapies, contraceptives, and antifungal agents.	Healthcare, pharmaceuticals & veterinary products	Not Available
CEDs000373	Dopaminergic agents?Dopaminergic agents are compounds that influence the dopamine system, primarily through agonistic or antagonistic actions at dopamine receptors.	Healthcare, pharmaceuticals & veterinary products	Not Available
CEDs000518	Electrically Stimulated Smoking Devices?Electrically stimulated smoking devices, commonly known as e-cigarettes or vape pens, utilize electrical components to heat a liquid solution, often containing nicotine, flavorings, and other additives, to produce an aerosol for inhalation.	Electrical & Electronic Equipment	PubChem
CEDs000537	Television Systems?Television systems can be a source of synthetic chemical contamination due to the various materials and components used in their manufacture and operation.	Electrical & Electronic Equipment	PubChem
CEDs000556	Cigar Cigarettes?Cigar cigarettes are a source of synthetic chemical contamination due to the combustion of various tobacco blends and additives.	Household cleaning & consumer products	PubChem
CEDs000559	Non Electric Simulated Smoking Devices?Non-electric simulated smoking devices, often designed to mimic the experience of smoking without combustion, can be sources of synthetic chemical contamination due to the materials and chemicals used in their construction and operation.	Household cleaning & consumer products	PubChem
CEDs000560	Other Smoking Requisites?Other smoking requisites, including items such as lighters, matches, and rolling papers, can introduce synthetic chemical contamination through various components and additives.	Household cleaning & consumer products	PubChem
CEDs000580	Manufacture Preparation Of Tobacco Products?The manufacture and preparation of tobacco products involve various processes that can result in the introduction of synthetic chemicals into the environment.	Industrial manufacturing & chemical processing	PubChem
CEDs000596	Acaricides?Acaricides are synthetic chemicals specifically designed to target and control mite populations that can damage crops and plants.	Agriculture & land management	PubChem
CEDs000597	Chemosterilants?Chemosterilants are synthetic chemicals designed to induce sterility in target pest populations, thereby controlling their reproduction and mitigating damage to crops.	Agriculture & land management	PubChem
CEDs000605	Pest Repellants?Pest repellents, often formulated from synthetic chemicals, are widely used to protect crops from insect infestations and other pests.	Agriculture & land management	PubChem
CEDs000610	Aftersun Products?Aftersun products are designed to soothe and hydrate the skin after sun exposure, often containing various synthetic chemicals such as emollients, preservatives, and fragrances.	Personal care & cosmetics	PubChem
CEDs000611	Anti Perspirants Or Body Deoderants?Antiperspirants and body deodorants commonly contain synthetic chemicals such as aluminum compounds, parabens, and synthetic fragrances.	Personal care & cosmetics	PubChem
CEDs000632	Apparel?Apparel production often involves the use of various synthetic chemicals, including dyes, finishing agents, and preservatives.	Textiles, leather & furnishings	PubChem
CEDs000671	Airplanes And Helicopters?Airplanes and helicopters are significant sources of synthetic chemical contamination primarily through the use of aviation fuels, lubricants, and de-icing agents.	Aviation & Aerospace	PubChem
CEDs000685	Ceramics?Ceramics can be a source of synthetic chemical contamination through various additives and processing agents used in their production.	Building & Construction	PubChem
CEDs000696	Nanotechnology?Nanotechnology involves the manipulation of materials at the molecular or atomic level, typically within the range of 1 to 100 nanometers.	Industrial manufacturing & chemical processing	PubChem
CEDs000735	Explosives?Explosives are chemical compounds or mixtures designed to undergo rapid decomposition, releasing energy in the form of gas and heat.	Defense & military infrastructure	PubChem
CEDs000744	Water, Wastewater, & Sewage Treatment?Water, wastewater, and sewage treatment processes are critical for managing and mitigating pollutants in water systems.	Wastewater, sanitation & biosolids	PubChem

Pathways

2 pathwaysPathway Source: PathBank

Cabergoline Mechanism of Action Action Pathway

Cabergoline Drug Metabolism Action Pathway

Targets

Structure	Protein	UniProt ID	Organism	Relationship	Details
Click to view 3D structure	5-hydroxytryptamine receptor 2B	P41595	Humans	Predicted (SEA)	Prediction Confidence Score 0.567 Applicability Domain 1.0 Statistical Significance 8.00e-04 Supporting Reference Compounds 686 E-value 6.22794
Click to view 3D structure	5-hydroxytryptamine receptor 1A	P19327	Rattus norvegicus	Predicted (SEA)	Prediction Confidence Score 0.483 Applicability Domain 0.784 Statistical Significance 0.0054 Supporting Reference Compounds 541 E-value 42.4278
Click to view 3D structure	D(2) dopamine receptor	P61169	Rat	Predicted (SEA)	Prediction Confidence Score 0.483 Applicability Domain 0.784 Statistical Significance 0.0064 Supporting Reference Compounds 528 E-value 49.7457
Click to view 3D structure	D(2) dopamine receptor	P14416	Humans	Predicted (SEA)	Prediction Confidence Score 0.474 Applicability Domain 1.0 Statistical Significance 0.0102 Supporting Reference Compounds 1103 E-value 79.3284
Click to view 3D structure	Alpha-2A adrenergic receptor	P08913	Humans	Predicted (SEA)	Prediction Confidence Score 0.473 Applicability Domain 1.0 Statistical Significance 0.0021 Supporting Reference Compounds 487 E-value 16.1148
Click to view 3D structure	D(1A) dopamine receptor	P21728	Humans	Predicted (SEA)	Prediction Confidence Score 0.472 Applicability Domain 1.0 Statistical Significance 0.0035 Supporting Reference Compounds 425 E-value 27.4808
Click to view 3D structure	D(1A) dopamine receptor	P18901	Rattus norvegicus	Predicted (SEA)	Prediction Confidence Score 0.466 Applicability Domain 0.784 Statistical Significance 0.0023 Supporting Reference Compounds 206 E-value 17.7496
Click to view 3D structure	5-hydroxytryptamine receptor 6	P50406	Humans	Predicted (SEA)	Prediction Confidence Score 0.352 Applicability Domain 0.405 Statistical Significance 0.017 Supporting Reference Compounds 536 E-value 132.655
Click to view 3D structure	5-hydroxytryptamine receptor 2C	P28335	Humans	Predicted (SEA)	Prediction Confidence Score 0.337 Applicability Domain 0.405 Statistical Significance 0.0316 Supporting Reference Compounds 823 E-value 246.315
Click to view 3D structure	D(3) dopamine receptor	P35462	Humans	Predicted (SEA)	Prediction Confidence Score 0.337 Applicability Domain 0.405 Statistical Significance 0.0356 Supporting Reference Compounds 861 E-value 277.221
Click to view 3D structure	D(2) dopamine receptor	P14416	Humans	Known	Not Available
Click to view 3D structure	5-hydroxytryptamine receptor 2A	P28223	Humans	Predicted (SEA)	Prediction Confidence Score 0.337 Applicability Domain 0.405 Statistical Significance 0.042 Supporting Reference Compounds 955 E-value 327.122
Click to view 3D structure	Alpha-2B adrenergic receptor	P18089	Humans	Predicted (SEA)	Prediction Confidence Score 0.334 Applicability Domain 0.405 Statistical Significance 0.0125 Supporting Reference Compounds 340 E-value 97.3894
Click to view 3D structure	Alpha-2C adrenergic receptor	P18825	Humans	Predicted (SEA)	Prediction Confidence Score 0.334 Applicability Domain 0.405 Statistical Significance 0.0147 Supporting Reference Compounds 386 E-value 114.438
Click to view 3D structure	D(4) dopamine receptor	P21917	Humans	Predicted (SEA)	Prediction Confidence Score 0.333 Applicability Domain 0.405 Statistical Significance 0.0302 Supporting Reference Compounds 524 E-value 235.416
Click to view 3D structure	5-hydroxytryptamine receptor 1A	P08908	Humans	Predicted (SEA)	Prediction Confidence Score 0.333 Applicability Domain 0.405 Statistical Significance 0.0409 Supporting Reference Compounds 953 E-value 318.403
Click to view 3D structure	5-hydroxytryptamine receptor 1B	P28564	Rattus norvegicus	Predicted (SEA)	Prediction Confidence Score 0.329 Applicability Domain 0.405 Statistical Significance 0.0091 Supporting Reference Compounds 154 E-value 70.5314
Click to view 3D structure	5-hydroxytryptamine receptor 7	P34969	Humans	Predicted (SEA)	Prediction Confidence Score 0.325 Applicability Domain 0.391 Statistical Significance 0.0312 Supporting Reference Compounds 565 E-value 242.656
Click to view 3D structure	Alpha-1A adrenergic receptor	P43140	Rattus norvegicus	Predicted (SEA)	Prediction Confidence Score 0.323 Applicability Domain 0.405 Statistical Significance 0.0148 Supporting Reference Compounds 208 E-value 115.528
Click to view 3D structure	Alpha-1D adrenergic receptor	P25100	Humans	Predicted (SEA)	Prediction Confidence Score 0.323 Applicability Domain 0.405 Statistical Significance 0.0149 Supporting Reference Compounds 258 E-value 115.917
Click to view 3D structure	Alpha-1B adrenergic receptor	P15823	Rattus norvegicus	Predicted (SEA)	Prediction Confidence Score 0.323 Applicability Domain 0.405 Statistical Significance 0.0076 Supporting Reference Compounds 130 E-value 59.2433
Click to view 3D structure	5-hydroxytryptamine receptor 5A	P47898	Humans	Predicted (SEA)	Prediction Confidence Score 0.315 Applicability Domain 0.391 Statistical Significance 0.0125 Supporting Reference Compounds 225 E-value 97.3115
Click to view 3D structure	Cytochrome P450 2D6	P10635	Humans	Predicted (SEA)	Prediction Confidence Score 0.315 Applicability Domain 0.405 Statistical Significance 0.0727 Supporting Reference Compounds 1130 E-value 566.12
Click to view 3D structure	Beta-1 adrenergic receptor	P08588	Humans	Predicted (SEA)	Prediction Confidence Score 0.304 Applicability Domain 0.323 Statistical Significance 0.0101 Supporting Reference Compounds 180 E-value 78.3942
Click to view 3D structure	D(2) dopamine receptor	P20288	Bos taurus	Predicted (SEA)	Prediction Confidence Score 0.302 Applicability Domain 0.405 Statistical Significance 0.0084 Supporting Reference Compounds 72 E-value 65.3155
Click to view 3D structure	Alpha-1A adrenergic receptor	P35348	Humans	Predicted (SEA)	Prediction Confidence Score 0.298 Applicability Domain 0.405 Statistical Significance 0.0383 Supporting Reference Compounds 376 E-value 298.163
Click to view 3D structure	5-hydroxytryptamine receptor 2A	P28223	Humans	Known	Not Available
Click to view 3D structure	5-hydroxytryptamine receptor 2C	P28335	Humans	Known	Not Available
Click to view 3D structure	Alpha-2B adrenergic receptor	P18089	Humans	Known	Not Available
Click to view 3D structure	D(1A) dopamine receptor	P21728	Humans	Known	Not Available
Click to view 3D structure	5-hydroxytryptamine receptor 1A	P08908	Humans	Known	Not Available
Click to view 3D structure	Alpha-2A adrenergic receptor	P08913	Humans	Known	Not Available
Click to view 3D structure	Alpha-2C adrenergic receptor	P18825	Humans	Known	Not Available
Click to view 3D structure	D(1B) dopamine receptor	P21918	Humans	Known	Not Available
Click to view 3D structure	D(3) dopamine receptor	P35462	Humans	Known	Not Available
Click to view 3D structure	5-hydroxytryptamine receptor 1D	P28221	Humans	Known	Not Available
Click to view 3D structure	D(4) dopamine receptor	P21917	Humans	Known	Not Available
Click to view 3D structure	5-hydroxytryptamine receptor 1B	P28222	Humans	Known	Agonism of 5-HT2B and 5-HT1B receptors is believed to be responsible for the fibrotic reactions and cardiac valvular disease associated with cabergoline use. (A2933)
Click to view 3D structure	5-hydroxytryptamine receptor 2B	P41595	Humans	Known	Agonism of 5-HT2B and 5-HT1B receptors is believed to be responsible for the fibrotic reactions and cardiac valvular disease associated with cabergoline use. (A2933)
Click to view 3D structure	5-hydroxytryptamine receptor 7	P34969	Humans	Known	Not Available
Click to view 3D structure	Alpha-1A adrenergic receptor	P35348	Humans	Known	Not Available
Click to view 3D structure	Alpha-1B adrenergic receptor	P35368	Humans	Known	Not Available
Click to view 3D structure	Alpha-1D adrenergic receptor	P25100	Humans	Known	Not Available
Click to view 3D structure	Beta-1 adrenergic receptor	P08588	Humans	Known	Not Available
Click to view 3D structure	Beta-2 adrenergic receptor	P07550	Humans	Known	Not Available
Click to view 3D structure	D(2) dopamine receptor	P14416	Humans	Known	Cabergoline is a long-acting dopamine receptor agonist with a high affinity for D2 receptors. This agonism has an anti-Parkinsonian effect. (A2946)

Concentrations

Not Available

External Links

DrugBank ID

DB00248

HMDB ID

HMDB0014393

FooDB ID

Not Available

Phenol Explorer ID

Not Available

KNApSAcK ID

Not Available

BiGG ID

Not Available

BioCyc ID

Not Available

METLIN ID

Not Available

PDB ID

Not Available

Wikipedia Link

Chemspider ID

ChEBI ID

PubChem Compound ID

Kegg Compound ID

YMDB ID

Not Available

ECMDB ID

Not Available

References

Synthesis Reference

DrugSyn.org

MSDS

Not Available

General References

Richard JL: Some major mycotoxins and their mycotoxicoses--an overview. Int J Food Microbiol. 2007 Oct 20;119(1-2):3-10. Epub 2007 Jul 31. [PubMed: 17719115]
Mantegani S, Brambilla E, Varasi M: Ergoline derivatives: receptor affinity and selectivity. Farmaco. 1999 May 30;54(5):288-96. [PubMed: 10418123]
Schiff PL: Ergot and its alkaloids. Am J Pharm Educ. 2006 Oct 15;70(5):98. [PubMed: 17149427]
Kvernmo T, Hartter S, Burger E: A review of the receptor-binding and pharmacokinetic properties of dopamine agonists. Clin Ther. 2006 Aug;28(8):1065-78. [PubMed: 16982285]
Pastor P, Tolosa E: [Cabergoline in the treatment of Parkinson's disease]. Neurologia. 2003 May;18(4):202-9. [PubMed: 12721865]
Curran MP, Perry CM: Cabergoline : a review of its use in the treatment of Parkinson's disease. Drugs. 2004;64(18):2125-41. [PubMed: 15341508]
Bracco F, Battaglia A, Chouza C, Dupont E, Gershanik O, Marti Masso JF, Montastruc JL: The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study. CNS Drugs. 2004;18(11):733-46. [PubMed: 15330687]
Miyagi M, Arai N, Taya F, Itoh F, Komatsu Y, Kojima M, Isaji M: Effect of cabergoline, a long-acting dopamine D2 agonist, on reserpine-treated rodents. Biol Pharm Bull. 1996 Nov;19(11):1499-502. [PubMed: 8951172]
Wikipedia. Ergoline. Last Updated 2 April 2010. - http://en.wikipedia.org/wiki/Ergoline
Wikipedia. Ergotism. Last Updated 6 April 2010. - http://en.wikipedia.org/wiki/Ergotism
Van den Enden, E. (2004). Illustrated Lecture Notes on Tropical Medicine. - http://www.itg.be/evde/
Wikipedia. Cabergoline. Last Updated 26 April 2010. - http://en.wikipedia.org/wiki/Cabergoline
RxList: The Internet Drug Index (2010). Dostinex (Cabergoline). - http://www.rxlist.com/dostinex-drug.htm

Cabergoline (CED0004293)

Structure for CHEM002153: Cabergoline

Structure